Anticancer Drugs Neratinib Oncology Pharmacology Physiotherapy

Neratinib (Mechanism of Action)

In this article we will discuss Neratinib (Mechanism of Action)

In this article, we will discuss Neratinib (Mechanism of Action). So, let’s get started.

Mechanism of Action

Neratinib is a kinase inhibitor that irreversibly binds to Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and HER4. In vitro, neratinib reduces EGFR and HER2 autophosphorylation, downstream MAPK and AKT signaling pathways, and showed antitumor activity in EGFR and/or HER2 expressing carcinoma cell lines. Neratinib human metabolites M3, M6, M7 and M11 inhibited the activity of EGFR, HER2 and HER4 in vitro. In vivo, oral administration of neratinib inhibited tumor growth in mouse xenograft models with tumor cell lines expressing HER2 and EGFR.


Cardiac Electrophysiology

The effect of Neratinib on the QTc interval was evaluated in a randomized, placebo and positive controlled, double-blind, single-dose, crossover study in 60 healthy subjects. At 2.4-fold the therapeutic exposures of Neratinib, there was no clinically relevant effect on the QTc interval.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.